Related Experiment Video
Updated: Jan 14, 2026
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
EGFR Activation and Conformational "Convergence": An Emerging Allosteric Model From Cancer Mutations
1Protein Dynamics and Mutation Lab, Department of Oncology-Pathology, Karolinska Institute, Sweden.
Abstract:
Since its isolation nearly 50 years ago, the Epidermal Growth Factor Receptor (EGFR) has become one of the most extensively studied oncogenes. However, scarce data on the full-length receptor, together with its flexibility, has left critical aspects of its activation mechanism unresolved. This has hampered the interpretation of mutations, which are highly asymmetric, tissue-specific, and linked to antagonistic drug sensitivities. While in lung cancer, oncogenic mutations target the kinase and respond to type-I tyrosine kinase inhibitors (TKIs), in brain glioblastoma (GBM), highly heterogeneous mutations focus on the ectodomain (ECD) but share preferential responses to inhibitors that target intermediate active/inactive features in the kinase. Here, we recapitulate current structural and mutational data to shed light on how its extra- and intracellular domains are coupled, with a special focus on an ECD transition state in GBM. This intermediate, first detected by antibodies and later captured in simulations, is characterized by the flexible rotation of the same extracellular fragment deleted in the most frequent GBM mutation, EGFRvIII. The convergence of missense and deletion ECD changes to flexibilize or remove the same piece, hallmarked by a cryptic epitope, offers an explanation for shared drug responses. Based on these observations, we discuss a putative allosteric mechanism, where the extracellular and intracellular sides are tightly coupled in preformed dimers, and the rigidity of the ECD is key to preventing kinase activation. While GBM mutations bypass the steric blockade, lung cancer mutants directly enhance catalytic activity, stabilizing antagonistic states and explaining their opposite drug sensitivities.
Insights
Epidermal Growth Factor Receptor (EGFR) mutations in brain glioblastoma (GBM) involve the ectodomain, unlike lung cancer mutations. This flexibility explains shared drug responses in GBM by revealing an intermediate state.
Area of Science:
- Molecular Biology
- Oncology
- Structural Biology
Background:
- The Epidermal Growth Factor Receptor (EGFR) is a key oncogene, but its activation mechanism remains incompletely understood due to limited full-length structural data and inherent flexibility.
- EGFR mutations exhibit tissue-specific patterns and influence drug sensitivity, particularly in lung cancer and glioblastoma (GBM).
- Lung cancer mutations primarily affect the kinase domain, while GBM mutations often target the ectodomain (ECD), yet share drug response profiles.
Purpose of the Study:
- To elucidate the coupling mechanism between the extracellular and intracellular domains of EGFR, focusing on an intermediate ectodomain transition state observed in GBM.
- To explain the shared drug responses in GBM by analyzing the structural impact of ectodomain mutations.
Main Methods:
- Recapitulation of existing structural and mutational data for EGFR.
- Analysis of antibody detection and molecular simulations to characterize an intermediate ECD state.
- Comparison of GBM and lung cancer mutation profiles and their impact on receptor activation.
Main Results:
- An intermediate ECD transition state, involving flexible rotation of a key fragment, is identified and linked to GBM mutations, including the common EGFRvIII deletion.
- Convergent missense and deletion mutations in the ECD of GBM target the same flexible region, suggesting a common mechanism.
- A cryptic epitope is associated with this intermediate state, offering a molecular basis for shared drug responses in GBM.
Conclusions:
- EGFR activation is regulated by an allosteric mechanism where extracellular and intracellular domains are coupled in preformed dimers, with ECD rigidity preventing kinase activation.
- GBM mutations bypass this steric blockade by flexibilizing the ECD, while lung cancer mutations directly enhance kinase activity, leading to distinct drug sensitivities.
- Understanding the EGFR ectodomain's role in GBM pathogenesis and drug response is crucial for developing targeted therapies.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Related Concept Videos
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:21Cancers Originate from Somatic Mutations in a Single Cell